FY2027 EPS Forecast for Kura Oncology Reduced by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management decreased their FY2027 earnings per share estimates for shares of Kura Oncology in a report released on Tuesday, November 4th. Brookline Capital Management analyst L. Cann now expects that the company will earn $2.94 per share for the year, down from their previous forecast of $2.96. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million.

Several other research firms have also recently commented on KURA. Zacks Research cut Kura Oncology from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 7th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. JMP Securities restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.96 on Wednesday. The stock has a market capitalization of $864.53 million, a price-to-earnings ratio of -4.41 and a beta of 0.35. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $19.73. The firm has a 50-day simple moving average of $9.08 and a 200-day simple moving average of $7.26.

Institutional Trading of Kura Oncology

Large investors have recently bought and sold shares of the business. State of Wyoming boosted its stake in shares of Kura Oncology by 45.8% during the third quarter. State of Wyoming now owns 12,172 shares of the company’s stock worth $108,000 after buying an additional 3,826 shares during the period. Thrivent Financial for Lutherans acquired a new stake in Kura Oncology during the 3rd quarter worth approximately $521,000. Nan Fung Trinity HK Ltd. acquired a new stake in Kura Oncology during the 3rd quarter worth approximately $2,043,000. Arizona State Retirement System lifted its position in Kura Oncology by 15.8% during the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock worth $181,000 after acquiring an additional 2,802 shares during the period. Finally, Foundations Investment Advisors LLC acquired a new stake in Kura Oncology during the 3rd quarter worth approximately $254,000.

Insider Transactions at Kura Oncology

In other news, CEO Troy Edward Wilson sold 36,615 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $327,338.10. Following the completion of the sale, the chief executive officer directly owned 246,853 shares of the company’s stock, valued at approximately $2,206,865.82. This represents a 12.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kathleen Ford sold 6,892 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $61,614.48. Following the completion of the sale, the chief operating officer directly owned 63,375 shares of the company’s stock, valued at $566,572.50. The trade was a 9.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 78,058 shares of company stock worth $697,839. Insiders own 6.40% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.